Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Greater understanding of the role of lipoproteins could support screening and efforts to develop treatments.

Some blood lipid biomarkers linked to cardiovascular disease risk are also associated with a lower risk of amyotrophic lateral sclerosis (ALS). ALS is the commonest form of motor neuron disease - a progressive nervous system disease that destroys nerve cells responsible for voluntary movement such as walking and talking.

The new insight is suggested by the findings of a large epidemiology study published online in the Journal of Neurology Neurosurgery & Psychiatry, and authored by members of the Oxford Motor Neuron Disease Centre in our Department. The study was funded by The Medical Research Council and the Motor Neurone Disease Association.

Single gene factors drive only a minority of cases of ALS, and in the remainder the causes of the condition are not well understood. Lower weight, higher levels of strenuous physical activity levels, and relatively good cardiovascular health have been shown by some studies to be risk factors for ALS, but the relationships are complex and the evidence inconsistent. 

Researchers are keen to identify biomarkers linked to ALS, which could ultimately lead to much earlier diagnosis, potentially before symptoms appear, and the hope of preventative treatments. 

Alexander Thompson et al used data from a very large epidemiological study to determine with more certainty the nature of any relationships between levels of biomarkers associated with cardiovascular disease and subsequent diagnosis of ALS. They used data for 502,409 people who enrolled in the UK Biobank study between March 2006 and October 2010 when aged 39 to 72 years. All had blood tests at enrolment and were followed for a median of 11.9 years.

The authors looked at the relationship between ALS and baseline blood levels of high and low density lipoprotein (HDL and LDL), total cholesterol, apolipoproteins A1 and B (apoA1 and apoB), triglycerides, glycated haemoglobin A1c (HbA1c) and creatinine. They also looked at the relationship between ALS and self-reported exercise and body mass index.

After controlling for age and sex, the authors found that higher HDL and apoA1 were associated with a lower risk of ALS. A higher total cholesterol:HDL ratio was associated with a higher risk of ALS.

When models incorporating multiple metabolic markers were used to assess risk of the condition, HDL and apoA1 continued to be associated with a reduced risk of ALS independent of other factors. Lower LDL and apoB levels were also associated with a decreased risk of ALS.

In further analysis, levels of LDL and apoB were shown to be higher long before diagnosis but lower in people closer to diagnosis, whereas HDL and apoA1 levels showed no such differences.

'The persistence of these findings in models controlling for statin use, smoking and vascular disease indicates that the association of lipid levels and ALS is not attributable to a confounding association between lipids, ALS and these factors,' the authors say.

This is an observational study, and as such, can't establish cause. The researchers also acknowledge certain limitations, including differences between study participants and the general population due to the nature of the Biobank recruitment processes, use of ICD10 and ICD9 diagnostic codes to identify ALS cases meant that some non-ALS motor neuron disease cases might be incorrectly included, and lack of data on common genetic causes of ALS.

There remain some inconsistencies across other published studies, reflecting different methodologies. Nevertheless, the authors conclude: 'This study adds to a growing literature documenting differences in the premorbid metabolic profile of those who eventually develop ALS.'

'In addition to providing novel insights into pathogenesis, this emphasises the need to consider a broader set of potential pre-symptomatic ALS biomarkers. Such markers might help to target population screening for ALS and also build confidence in future trials of preventative therapy.'

Read the paper

Similar stories

Viewing self-harm images on the internet and in social media usually causes harm, according to new review

Clinical researchers have reviewed the international research evidence regarding the impact of viewing images of self-harm on the internet and in social media.

Can humans hibernate?

Illuminating new TEDx Talk from Professor of Sleep Physiology Vladyslav Vyazovskiy

European Platform for Neurodegenerative Diseases launches repository of cohorts for researchers

The new Cohort Catalogue will facilitate discovery of over 60 neurodegeneration research cohorts from 17 countries across Europe

New insights into chemogenetic designer drugs to enhance our study of behaviour

A collaborative team of researchers in DPAG and Pharmacology led by Dr Lukas Krone have uncovered striking new data demonstrating that two widely used designer drugs used to turn populations of neurons on and off in the brain cause unexpected effects on sleep. These results demonstrate a critical need to improve chemogenetic approaches in behavioural studies.

Researchers win UK Dementia Research Institute Grand Challenge Award to identify early signs of Alzheimer's

The MRC Brain Network Dynamics Unit has received funding for a multi-year research partnership designed to advance the understanding of early changes to the operations of brain circuits in Alzheimer's disease.

Ensuring LGBTQI+ people are treated fairly in mental health data

Andrey Kormilitzin outlines a new participatory study aimed at improving AI to take account of LGBTQI+ people so that their needs are better met by mental health services.